Outset Medical, Inc. (NASDAQ:OM – Get Free Report) General Counsel John L. Brottem sold 20,492 shares of the company’s stock in a transaction on Monday, January 13th. The stock was sold at an average price of $0.81, for a total transaction of $16,598.52. Following the transaction, the general counsel now owns 205,028 shares of the company’s stock, valued at approximately $166,072.68. The trade was a 9.09 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.
Outset Medical Price Performance
Outset Medical stock opened at $0.81 on Wednesday. The company has a debt-to-equity ratio of 4.12, a quick ratio of 5.04 and a current ratio of 6.49. Outset Medical, Inc. has a one year low of $0.44 and a one year high of $5.22. The company has a market cap of $42.67 million, a P/E ratio of -0.29 and a beta of 2.05. The business has a fifty day moving average of $1.01 and a two-hundred day moving average of $1.39.
Analysts Set New Price Targets
Separately, Royal Bank of Canada restated a “sector perform” rating and issued a $3.00 price objective on shares of Outset Medical in a research report on Tuesday, January 7th.
Institutional Trading of Outset Medical
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Vanguard Personalized Indexing Management LLC purchased a new position in Outset Medical in the second quarter valued at about $49,000. Huntington National Bank grew its holdings in shares of Outset Medical by 46.2% in the 3rd quarter. Huntington National Bank now owns 63,306 shares of the company’s stock worth $43,000 after acquiring an additional 20,000 shares during the period. National Bank of Canada FI grew its holdings in shares of Outset Medical by 79.2% in the 3rd quarter. National Bank of Canada FI now owns 52,407 shares of the company’s stock worth $35,000 after acquiring an additional 23,164 shares during the period. Squarepoint Ops LLC increased its stake in Outset Medical by 74.1% in the 2nd quarter. Squarepoint Ops LLC now owns 80,300 shares of the company’s stock valued at $309,000 after purchasing an additional 34,187 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in Outset Medical during the second quarter worth $259,000.
About Outset Medical
Outset Medical, Inc, a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables.
See Also
- Five stocks we like better than Outset Medical
- How to Evaluate a Stock Before BuyingÂ
- The Fed Is More Likely to Hike Than Cut Rates in 2025
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Investors Navigate Uncertainty by Seeking Refuge in Gold and Oil
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- Archer Aviation Shares Slide, Now Bargain Priced for 2025
Receive News & Ratings for Outset Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Outset Medical and related companies with MarketBeat.com's FREE daily email newsletter.